Literature DB >> 32279709

Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.

Werner Poewe1, Philipp Mahlknecht2.   

Abstract

The cardinal motor features of Parkinson disease (PD) are driven by striatal dopamine deficiency. Pharmacologic dopamine substitution is the mainstay of drug treatment of PD. Levodopa is still the most efficacious drug to treat PD motor symptoms. MAO-B inhibitors and dopamine agonists are useful options. The main limitation of levodopa is the development of motor response fluctuations and drug-induced dyskinesias. Adjunct MAO-B and COMT inhibitors as well as dopamine agonists and continuous infusions of levodopa intestinal gel or subcutaneous apomorphine are efficacious in reducing motor fluctuations and amantadine is the only drug with established efficacy in reducing dyskinesias.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopamine; Dyskinesia; Guideline; Motor fluctuations; Movement disorders society (MDS) evidence-based medicine (EBM) review update; Parkinson disease (PD); Recommendation; Treatment

Year:  2020        PMID: 32279709     DOI: 10.1016/j.ncl.2019.12.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  12 in total

1.  High-quality nursing intervention can improve negative emotions, quality of life and activity of daily living of elderly patients with Parkinson's disease.

Authors:  Yihui Gui; Youya Zhou
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.

Authors:  Chunxiao Wu; Hongji Guo; Yingshan Xu; Luping Li; Xinyu Li; Chunzhi Tang; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.750

Review 3.  Peripheral electrical stimulation to reduce pathological tremor: a review.

Authors:  Alejandro Pascual-Valdunciel; Grace W Hoo; Simon Avrillon; Filipe Oliveira Barroso; Jennifer G Goldman; Julio C Hernandez-Pavon; José L Pons
Journal:  J Neuroeng Rehabil       Date:  2021-02-15       Impact factor: 4.262

4.  Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease.

Authors:  Robert A Hauser; Ryan R Walsh; Rajesh Pahwa; Dustin Chernick; Andrea E Formella
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

Review 5.  Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Authors:  Philipp Mahlknecht; Kathrin Marini; Mario Werkmann; Werner Poewe; Klaus Seppi
Journal:  Transl Neurodegener       Date:  2022-02-21       Impact factor: 8.014

6.  Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.

Authors:  Robert A Hauser; Judy Lytle; Andrea E Formella; Caroline M Tanner
Journal:  NPJ Parkinsons Dis       Date:  2022-03-18

Review 7.  Therapeutic Devices for Motor Symptoms in Parkinson's Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials.

Authors:  Joji Fujikawa; Ryoma Morigaki; Nobuaki Yamamoto; Teruo Oda; Hiroshi Nakanishi; Yuishin Izumi; Yasushi Takagi
Journal:  Front Aging Neurosci       Date:  2022-03-29       Impact factor: 5.702

8.  Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.

Authors:  Katarzyna Smilowska; Daniel J van Wamelen; Tomasz Pietrzykowski; Alexander Calvano; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin; Per Odin; K Ray Chaudhuri
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 9.  Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles.

Authors:  Ha Thi Thu Do; Jungsook Cho
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

Review 10.  Using multi-organ culture systems to study Parkinson's disease.

Authors:  Orly Reiner; Tamar Sapir; Arpan Parichha
Journal:  Mol Psychiatry       Date:  2020-11-05       Impact factor: 13.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.